Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/cr0ph/staging.phastar.com/wp-includes/functions.php on line 6260
Cushing Syndrome: Integrated Safety & Efficacy ISS
Abstract teal data cluster on a dark background

Delivering Integrated Safety and Efficacy Analyses in Cushing Syndrome

1 minute read

Published: October 6th, 2025

When faced with evolving analysis plans, minimal client infrastructure, and shifting output volumes, Phastar delivered high-quality ISS and ISE outputs for Cushing syndrome clinical studies. 

By combining automation, custom macros, and strategic agility within an FSP model, our team adapted quickly to changing sponsor needs—ensuring consistent quality and on-time delivery despite significant mid-project changes. 

This case study demonstrates how innovation, collaboration, and flexibility can transform complex integration challenges into regulatory-ready solutions that add lasting value for the sponsor. 

Complete the form to download the full case study.

Related articles

Protecting Trial Integrity- Independent Interim Analysis and IDMC Support in a Phase II Breast Cancer Study

Protecting Trial Integrity- Independent Interim Analysis and IDMC Support in a Phase II Breast Cancer Study

October 29th, 2026 1 minute read

Interim analyses and safety reviews play a critical role in clinical trial oversight, providing decision-makers with ...

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

July 20th, 2026 1 minute read

Designing a first-in-human study is challenging. Designing one for a novel reproductive therapy with limited prior da...

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

July 20th, 2026 1 minute read

Accelerating clinical development requires more than speed, it demands a careful balance between innovation, scientif...